Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol (2002) 2.90

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol (2005) 1.65

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog (2009) 1.29

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25

Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol (2007) 1.22

Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol (2004) 1.17

Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09

An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08

Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06

Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J Virol (2005) 1.03

An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations. J Mol Biol (2007) 0.99

Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol (2007) 0.93

The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology (2007) 0.82

Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope. Retrovirology (2008) 0.80

Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms. J Virol (2014) 0.79

Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. Virology (2010) 0.79

Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1. AIDS Res Hum Retroviruses (2015) 0.75

Movements of HIV-1 genomic RNA-APOBEC3F complexes and PKR reveal cytoplasmic and nuclear PKR defenses and HIV-1 evasion strategies. Virus Res (2015) 0.75

HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19

Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem (1985) 26.05

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69

Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13

Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 15.63

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64

The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol (1992) 10.25

HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72

HIV entry and its inhibition. Cell (1998) 9.42

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36

Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell (1999) 4.97

Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85

Glycobiology. Annu Rev Biochem (1988) 4.51

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21

Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (1996) 3.84

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol (2000) 3.52

Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35

A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol (1996) 3.26

Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol (1998) 3.11

CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04

Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95

HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J (1997) 2.86

Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38

Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol (2001) 2.32

Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol (1992) 2.30

A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28

Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol (1999) 2.24

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23

Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (2000) 2.16

N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07

Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J Virol (1997) 1.98

A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem (2000) 1.80

Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J Virol (1997) 1.77

Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science (1992) 1.76

Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol (1997) 1.75

Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol (1998) 1.69

Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol (2000) 1.55

The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol (2000) 1.50

Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47

A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci U S A (2000) 1.45

Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology (1998) 1.38

Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. J Virol (2002) 1.37

N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J Virol (2000) 1.32

Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol (2001) 1.29

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem (1999) 1.28

Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol (2000) 1.21

Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol (2000) 1.14

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci U S A (1999) 1.14

Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol (2001) 1.10

Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 1.05

Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus. J Virol (2000) 1.04

Sulfation of the human immunodeficiency virus envelope glycoprotein. J Virol (1992) 0.92

Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94

NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. Proc Natl Acad Sci U S A (1975) 9.15

Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter. Nature (1991) 4.84

Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A (1994) 4.07

Structure-activity relationships of an exotoxin of Pseudomonas aeruginosa. Infect Immun (1977) 3.63

Unexpectedly large size of globin messenger ribonucleic acid. Proc Natl Acad Sci U S A (1971) 3.56

Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44

Evidence for a glycoprotein "signal" involved in transport between subcellular organelles. Two membrane glycoproteins encoded by murine leukemia virus reach the cell surface at different rates. J Biol Chem (1982) 3.24

Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun (1977) 3.17

CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04

Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol (2000) 2.95

An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73

Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc Natl Acad Sci U S A (1999) 2.62

Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol (1989) 2.52

Improved methods for purification and assay of eukaryotic messenger ribonucleic acids and ribosomes. Quantitative analysis of their interaction in a fractionated reticulocyte cell-free system. J Biol Chem (1975) 2.30

Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus. J Virol (1977) 2.26

Isotopic labeling and analysis of phosphoproteins from mammalian ribosomes. Methods Enzymol (1974) 2.19

Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J Virol (1991) 2.05

Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci U S A (1988) 2.02

Glycoprotein encoded by the Friend spleen focus-forming virus. J Virol (1979) 1.89

Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol (1991) 1.81

Ping-pong amplification of a retroviral vector achieves high-level gene expression: human growth hormone production. J Virol (1990) 1.78

Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J Virol (1997) 1.77

Gene selection in hemoglobin and in antibody-synthesizing cells. Science (1972) 1.76

The membrane glycoprotein of Friend spleen focus-forming virus: evidence that the cell surface component is required for pathogenesis and that it binds to a receptor. J Virol (1987) 1.67

Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int (1996) 1.66

The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J Virol (1991) 1.58

A sodium-dependent neutral-amino-acid transporter mediates infections of feline and baboon endogenous retroviruses and simian type D retroviruses. J Virol (1999) 1.58

Phosphorylation of ribosomal proteins in rabbit reticulocytes. Characterization and regulatory aspects. Biochemistry (1970) 1.56

Polymorphisms of the cell surface receptor control mouse susceptibilities to xenotropic and polytropic leukemia viruses. J Virol (1999) 1.55

Competition between globin messenger ribonucleic acids for a discriminating initiation factor. J Biol Chem (1977) 1.51

A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily. J Virol (1999) 1.48

Loss of leukemogenicity caused by mutations in the membrane glycoprotein structural gene of Friend spleen focus-forming virus. Proc Natl Acad Sci U S A (1983) 1.47

Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol (1997) 1.47

Plasma membrane glycoproteins encoded by cloned Rauscher and Friend spleen focus-forming viruses. J Virol (1980) 1.46

Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J Virol (1997) 1.44

Phosphorylation of ribosomal proteins in rabbit reticulocytes. A cell-free system with ribosomal protein kinase activity. Biochemistry (1971) 1.43

The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible species. J Virol (1995) 1.43

Cell surface receptors for gammaretroviruses. Curr Top Microbiol Immunol (2003) 1.42

Role of the PU.1 transcription factor in controlling differentiation of Friend erythroleukemia cells. Mol Cell Biol (1992) 1.41

Molecular cloning of biologically active Rauscher spleen focus-forming virus and the sequences of its env gene and long terminal repeat. J Virol (1984) 1.38

A murine leukemia virus mutant with a temperature-sensitive defect in membrane glycoprotein synthesis. Cell (1979) 1.34

Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem (1995) 1.34

Synthesis of erythrocyte-specific proteins in cultured friend leukemia cells. Cell (1975) 1.33

Constitutive expression of steel factor gene by human stromal cells. Blood (1993) 1.33

Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene. Proc Natl Acad Sci U S A (1990) 1.33

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem (1999) 1.28

Disulfide bonding controls the processing of retroviral envelope glycoproteins. J Biol Chem (1991) 1.27

Effects of ecotropic murine retroviruses on the dual-function cell surface receptor/basic amino acid transporter. J Biol Chem (1992) 1.27

Role of a membrane glycoprotein in Friend virus-induced erythroleukemia: studies of mutant and revertant viruses. Virology (1985) 1.25

Genetic and sialylation sources of heterogeneity of the murine leukemia virus membrane envelope glycoproteins gp69/71. J Biol Chem (1979) 1.24

A common site for immortalizing proviral integrations in Friend erythroleukemia: molecular cloning and characterization. J Virol (1989) 1.23

Heterogeneous metabolism and subcellular localization of a potentially leukemogenic membrane glycoprotein encoded by Friend erythroleukemia virus. Isolation of viral and cellular processing mutants. J Biol Chem (1982) 1.22

The Ets-related transcription factor PU.1 immortalizes erythroblasts. Mol Cell Biol (1993) 1.20

Potentiation of hemoglobin messenger ribonucleic acid. A step in protein synthesis initiation involving interaction of messenger with 18 S ribosomal ribonucleic acid. J Biol Chem (1975) 1.20

Leukemogenic membrane glycoprotein encoded by Friend spleen focus-forming virus: transport to cell surfaces and shedding are controlled by disulfide-bonded dimerization and by cleavage of a hydrophobic membrane anchor. J Virol (1989) 1.18

Glycosylation and intracellular transport of membrane glycoproteins encoded by murine leukemia viruses. Inhibition by amino acid analogues and by tunicamycin. J Biol Chem (1982) 1.15

Host-range control of a retroviral disease: Friend erythroleukemia. Trends Microbiol (1995) 1.13

Changes in RNA and protein metabolism preceding onset of hemoglobin synthesis in cultured Friend leukemia cells. Dev Biol (1976) 1.12

A tagged helper-free Friend virus causes clonal erythroblast immortality by specific proviral integration in the cellular genome. J Virol (1988) 1.11

The ribosomal subunit--polyribosome cycle in protein synthesis of embryonic skeletal muscle. Biochemistry (1969) 1.08

Relationship of Friend murine leukemia virus production to growth and hemoglobin synthesis in cultured erythroleukemia cells. J Virol (1976) 1.08

Cell surface site for mitogenic interaction of erythropoietin receptors with the membrane glycoprotein encoded by Friend erythroleukemia virus. J Biol Chem (1993) 1.07

Reduced leukemogenicity caused by mutations in the membrane glycoprotein gene of Rauscher spleen focus-forming virus. J Virol (1984) 1.07

Cellular and species resistance to murine amphotropic, gibbon ape, and feline subgroup C leukemia viruses is strongly influenced by receptor expression levels and by receptor masking mechanisms. J Virol (2000) 1.06

Immunoselection of mutants deficient in cell surface glycoproteins encoded by murine erythroleukemia viruses. Proc Natl Acad Sci U S A (1980) 1.05

Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 1.05

Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus. J Virol (2000) 1.04

Roles of helper and defective retroviral genomes in murine erythroleukemia: studies of spleen focus-forming virus in the absence of helper. J Virol (1985) 1.04

Expression of the silent hemoglobin gene in sheep. Studies of the globin messenger ribonucleic acids. J Biol Chem (1972) 1.03

A weakly pathogenic Rauscher spleen focus-forming virus mutant that lacks the carboxyl-terminal membrane anchor of its envelope glycoprotein. J Virol (1985) 1.02

Control of cationic amino acid transport and retroviral receptor functions in a membrane protein family. J Biol Chem (1994) 1.02

Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process. J Virol (1996) 1.02

Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol (2000) 1.02

Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1. J Biol Chem (1999) 1.01

A comprehensive approach to mapping the interacting surfaces of murine amphotropic and feline subgroup B leukemia viruses with their cell surface receptors. J Virol (2000) 1.01

Effect of cyclic adenosine 3':5'-monophosphate on ribosomal protein phosphorylation in reticulocytes. J Biol Chem (1974) 1.01

Mutant cells that abnormally process plasma membrane glycoproteins encoded by murine leukemia virus. Cell (1981) 1.01

Frequent substitution polymorphisms in African green monkey CCR5 cluster at critical sites for infections by simian immunodeficiency virus SIVagm, implying ancient virus-host coevolution. J Virol (2001) 1.00

The switch from fetal to adult hemoglobin in humans: evidence suggesting a role for gamma-beta gene linkage. Ann N Y Acad Sci (1974) 0.98

Cell surface receptors for murine leukemia viruses: two assays and their implications. Virology (1985) 0.97

Role of a membrane glycoprotein in Friend virus erythroleukemia: nucleotide sequences of nonleukemogenic mutant and spontaneous revertant viruses. J Virol (1986) 0.97

A Friend virus mutant that overcomes Fv-2rr host resistance encodes a small glycoprotein that dimerizes, is processed to cell surfaces, and specifically activates erythropoietin receptors. J Virol (1993) 0.97

Splenic accumulation of interleukin-3-dependent hematopoietic cells in Friend erythroleukemia. J Virol (1989) 0.97

Synthesis of chicken hemoglobins during erythrocyte differentiation. Biochim Biophys Acta (1967) 0.96

Modulation of ecotropic murine retroviruses by N-linked glycosylation of the cell surface receptor/amino acid transporter. J Virol (1996) 0.96

Mutations in the env gene of friend spleen focus-forming virus overcome Fv-2r-mediated resistance to Friend virus-induced erythroleukemia. J Virol (1992) 0.95

Turnover of phosphoryl groups in reticulocyte ribosomal phosphoproteins. J Biol Chem (1972) 0.94

An enhancer sequence instability that diversifies the cell repertoire for expression of a murine leukemia virus. Virology (1988) 0.92

gp120 envelope glycoproteins of human immunodeficiency viruses competitively antagonize signaling by coreceptors CXCR4 and CCR5. Proc Natl Acad Sci U S A (1998) 0.92

Genetic structure of Rauscher spleen focus-forming virus. J Virol (1983) 0.92

Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J Biol Chem (1994) 0.91

Phosphorylation of ribosomal proteins in sarcoma 180 tumor cells. J Biol Chem (1972) 0.90

Frequent hereditable shutdown of murine retrovirus gene expression in murine cell lines. Mol Cell Biol (1984) 0.88

Role of partial proteolysis in processing murine leukemia virus membrane envelope glycoproteins to the cell surface. A viral mutant with uncleaved glycoprotein. J Biol Chem (1982) 0.88

Targeting retroviral vectors to specific cells. Science (1995) 0.87